

Disseminated Coinfection by *Mycobacterium fortuitum* and *Talaromyces marneffe* in a Non-HIV Case

Hongchun Huang^{1,*}Jingmin Deng^{2,*}Caixia Qin¹Jianpeng Zhou³Minchao Duan⁴

¹Department of Respiratory and Critical Care Medicine, Guangxi Autonomous Regional Jiangbin Hospital, Nanning, Guangxi, 530021, People's Republic of China; ²Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021, People's Republic of China; ³Department of Respiratory and Critical Care Medicine, The First People's Hospital of Nanning, Nanning, Guangxi, 530022, People's Republic of China; ⁴Department of Respiratory and Critical Care Medicine, Guangxi Medical University Wuming Affiliated Hospital, Nanning, Guangxi, 530199, People's Republic of China

*These authors contributed equally to this work

Background: *Mycobacterium fortuitum* is a rapidly growing non-tuberculous mycobacterium (NTM) with weak pathogenicity. Here, we present a rare case of disseminated *M. fortuitum* and *Talaromyces marneffe* coinfection in a human immunodeficiency virus (HIV) negative patient.

Case Presentation: A 28-year-old female was admitted to our hospital due to 2 months of swelling of lymph nodes on the right side of her cervix, accompanied by repeated low fever for more than 1 month. Biopsy of the right cervical lymph node and endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TBNA) both suggested granulomatous inflammation. The bacterial culture and mycobacteria examination of the lesion as well as HIV antibody test were all negative. Disseminated *T. marneffe* infection was diagnosed by the quantitative polymerase chain reaction (qPCR) results from the blood showing 1798 copies/ul. In the meantime, treatment with amphotericin B combined with cefoxitin was administered for suspected NTM infection. However, the once-dropped fever recurred and the lymph nodes continued to swell. Metagenomics next-generation sequencing (mNGS) detection of the lymph nodes indicated *M. fortuitum*. After combination treatment with amphotericin B, voriconazole, linazolidamide, and imipenem, the patient's body temperature returned to normal, the lymph node swelling was gradually reduced, and the lung lesion was absorbed.

Conclusion: We report the first case of an HIV-negative patient diagnosed with disseminated *M. fortuitum* and *T. marneffe* coinfection with nonspecific clinical manifestation, in order to heighten awareness of these infections.

Keywords: *Mycobacterium fortuitum*, *Talaromyces marneffe*, coinfection, non-HIV

Introduction

Mycobacterium fortuitum is widely distributed in natural environments with strong survivability¹ and can cause cutaneous and pulmonary infection, lymphadenitis, and disseminated disease. *M. fortuitum* pulmonary disease is associated with multiple conditions, such as gastroesophageal disease² and structural pulmonary disorders, while disseminated disease is usually associated with immunodeficiency disorders.³ Pathogenesis of NTM remains unclear and potential pathogenicity factors include hydrophobic outer membrane rich in lipids, surface adhesive ability, biofilm and aerosol formation.⁴ Macrophages are critical in the host's immune response to NTM. Specifically, the pathogen-recognition receptors of macrophages recognize pathogen-associated molecular patterns on the NTM.

Correspondence: Minchao Duan
Department of Respiratory and Critical Care Medicine, Guangxi Medical University Wuming Affiliated Hospital, 26 Yongning Road, Wuming District, Nanning, Guangxi, 530199, People's Republic of China
Tel/Fax +86 15507711966
Email fortuitum@sohu.com

The macrophage then phagocytoses the NTM to form a phagosome, which fuses with the lysosome to form a phagolysosome to eliminate NTM. Macrophages act as antigen-presenting cells to trigger downstream activation of cellular and humoral adaptive immune responses. Macrophages can also kill NTM by producing antimicrobial active substances such as reactive oxygen species and reactive nitrogen species or by autophagy/necrosis mechanisms. NTM can evade the attack of the immune system by impairing phagosome maturation and autophagy/necrosis and promoting chronic infection.⁵ There is some evidence that NTM uses apoptotic macrophages to facilitate the spreading and survival in the host.⁶ Besides, in response to stimuli from NTM pathogens, the macrophage lineage expresses polarized functional properties, namely activated macrophages (M1) and activated macrophages (M2), with M2 polarization regulating immunity and preventing NTM injury during the advanced stages of infection, which is a critical mechanism of intracellular infection.^{7,8} Moreover, granuloma is also a sanctuary for NTM. In a zebrafish model, *M. fortuitum* can invade macrophages to develop mycobacterial granuloma, leading to chronic infection.⁹

As an intracellular pathogen, *T. marneffei* also inhibits phagosome maturation.¹⁰ *T. marneffei* can also withstand host-cell defenses such as antioxidants, heat shock proteins, and well-conserved mitogen-activated protein kinases signaling cascades.¹¹ *T. marneffei* is capable of driving macrophage polarization,¹² but it remains unclear if *T. marneffei* can induce macrophages to M2 polarization in order to survive in the host during infection.

Clinically, *M. fortuitum* usually causes colonized or transient infection in respiratory tracts.^{13,14} Coinfection by *M. fortuitum* and another intracellular pathogen has been reported in patients with immunodeficiency such as acquired immune deficiency syndrome but not in healthy individuals.^{15,16} Coinfections of *T. marneffei* with other NTM have also been reported,^{17–21} but not with *M. fortuitum*. *M. fortuitum* and *T. marneffei* are opportunistic pathogens, with the majority of cases of disseminated infection found in patients with immunodeficiency diseases.^{22–24} In our case, a non-HIV patient had coinfection with two pathogens, and we attempted to rule out potential primary immunodeficiency.

Here, we report the first case of disseminated *M. fortuitum* and *T. marneffei* coinfection in an HIV-negative patient with no specific clinical symptoms and a difficult early diagnosis, to provide clinical experience.

Case Presentation

A 28-year-old female was admitted to our hospital on August 17, 2017, with lymphadenomegaly on her right cervical area for approximately 2 months and repeated fever for more than 1 month, accompanied by a red rash, edema, and painful subcutaneous nodules in bilateral legs. Physical examination revealed lymphadenopathy in the right cervical bone and painful erythema nodosum in the bilateral calf. The patient had a history of pet rat bites in 2015.

Laboratory tests showed that hemoglobin (9.4 g/dL) and hematocrit (28.8%) levels were decreased, while white blood cell count ($16.27 \times 10^9/L$), neutrophils (78.6%), platelet count ($418 \times 10^9/L$), blood C-reactive protein (138.15 mg/L) and erythrocyte sedimentation rate (88 mm/h) were elevated. HIV serology and serum cryptococcal capsular antigen tests were negative. Immunoglobulin levels and lymphocyte subsets were normal. T cell spot test (T-SPOT) was indeterminate. Culture of blood, sputum, bronchoalveolar lavage fluid (BALF), and skin lesions were all negative. Chest computed tomography (CT) displayed patchy infiltrates in the right upper lung with enlargement of hilus pulmonis and mediastinal lymph nodes (Figure 1A). Pathological examination of the cervical lymph nodes suggested granulomatous inflammation, but acid-fast staining and periodic acid-Schiff (PAS) staining were negative (Figure 2A and B). EBUS-TBNA biopsy examination showed scattered granulomatous inflammation. During the course, empirical treatments with cefoxitin (CFX), levofloxacin (LVFX), moxifloxacin (MFX), cefodizime (CDZ), clarithromycin (CLA), etimicin (ETM) and anti-tuberculosis isoniazid (H), rifampicin (R), pyrazinamide (Z), ethambutol (E) regimen were successively administered, but no improvement was observed. By the end of October 2017, the patient developed pain in the head, right shoulder, gingiva, and knee-joint. Cerebrospinal fluid examination was normal, its smear and culture were all negative. Although bone marrow biopsy was consistent with infection and there was no evidence of hematological malignancy, the culture of bone marrow and lymph node tissue was both negative. Pathology examination of cervical lymph nodes showed suppurative necrotizing lymphadenitis, no fungus, and PAS (-). Positron emission tomography-computed tomography displayed enlargement of multiple lymph nodes of the right hilar, mediastinum, right supraclavicular and right neck, splenomegaly and increased bone metabolism in multiple places. The symptoms persisted after multiple rounds of antibiotic treatments, raising the possibility of a fungal infection. As the patient had a history of rat bites, an important natural reservoir for *T. marneffei*, we




Figure 1 (A and B) shows lymph node enlargement in the hilus pulmonis zone; (B–E) shows that enlarged lymph nodes shrank gradually in the hilus pulmonis zone.




Figure 2 (A and B) pathological examination of H&E staining (H&E, 100×; H&E, 400×) from the cervical lymph nodes suggested granulomatous inflammation. Granulomas is composed of epithelioid cells in the lymph nodes. PAS(-).

conducted *T. marneffeii* qPCR and obtained a result of 1798 copies/uL. Therefore, the patient was diagnosed with disseminated *T. marneffeii* infection, and intravenous antifungal therapy with amphotericin B liposome (AMPB) commenced on November 6, 2017. Owing to suspicion of coinfection with NTM, the patient was also treated with cefoxitin beginning on November 10, 2017. Subsequently, her body temperature dropped to normal, and symptoms of cough and sputum improved. The patient returned to the local hospital and continued treatment with itraconazole and cefoxitin.

However, the lymph nodes remained enlarged. In December 2018, the patient presented with hemoptysis and recurrent intermittent fever, cough, sputum, fever, and rash. The patient presented with recurrent fever, rash and lymph node enlargement, which did not improve despite treatment with various antibiotics and anti-infective treatment for

T. marneffeii and *M. tuberculosis*. The pathological manifestations were granulomatous inflammation, but we could not rule out NTM infection because the cultures for *M. tuberculosis* and NTM were negative. Therefore, we performed an mNGS test, which revealed *M. fortuitum* in the lymph nodes. Additionally, in January 2020, qPCR analysis of a BALF sample detected *T. marneffeii*. The patient was diagnosed with coinfection with *M. fortuitum* and *T. marneffeii* and was treated with a combination of amphotericin B, voriconazole (VRC), linezolid (LZD) and ETM. Her body temperature returned to normal and respiratory symptoms improved. On March 19, 2020, chest CT showed patchy infiltrates, banded and nodular shadows, as well as pleural effusion (Figure 3A). Emission computed tomography suggested abnormal concentration of imaging agent in various parts of the bone. One month later, the therapy was adjusted to a combination regimen of VRC, LZD,



Figure 3 (A) Chest CT shows patchy infiltrates, banded and nodular shadows, pleural effusion. (A–C) Lesions in the lower lobe of the right lung and the pleural effusion absorbed gradually.

MFX and CLA, which have continued to date. During follow-up in May and August 2020, the patient had no fever, the symptoms of cough and sputum had improved, and the rash had subsided. Re-examination of chest CT indicated that the enlarged hilar lymph nodes had gradually shrank (Figure 1B–E), and the lung lesions were significantly absorbed (Figure 3A–C). The patient experienced significant pain for more than 2 years between onset to the definitive diagnosis. The hospitalization and drug administration process throughout the history is summarized in Figure 4. Unfortunately, we overlooked the possibility of immunodeficiency in HIV-negative patient coinfecting with *M. fortuitum* and *T. marneffei*.

Discussion and Conclusions

The diagnosis of disseminated NTM infection was mainly based on positive blood culture, followed by positive culture of bone marrow, liver, and lymph node tissue.²⁵

In this case, we detected *M. fortuitum* in the lymph node samples, which is the best evidence of tissue infection, rather than colonization. Meanwhile, we made the diagnosis of disseminated *T. marneffei* by the detection of high copies of *T. marneffei* with qPCR.²⁶ The patient was finally diagnosed with disseminated *M. fortuitum* and *T. marneffei* infection.

We noticed that the patient had recurrent skin rashes throughout the disease. Either *M. fortuitum* infection or *T. marneffei* infection has cutaneous manifestation. Clinical signs of *M. fortuitum* infection are abscess, nodule, plaque, and papule. The most commonly involved sites are the legs.²⁷ This is similar to our case of painful erythema nodosum in the bilateral legs. While for *T. marneffei* infection, characteristic skin manifestations are umbilicated papules.²⁸ The skin lesions are mainly distributed on the face, scalp, upper extremities, and




Figure 4 Treatment and manifestation timeline.

Abbreviations: CFX, cefoxitin; LVFX, levofloxacin; MFX, moxifloxacin; CDZ, cefodizime; CLA, clarithromycin; ETM, etimicin; H, isoniazid; R, rifampicin; Z, pyrazinamide; E, ethambutol; AMPB, amphotericin B liposomes; VRC, voriconazole; LZD, linezolid.

trunk. Immune deficiency and trauma history are risk factors for NTM skin infections.²⁹ In the case of *M. fortuitum*, patients with single skin lesions are almost always immunocompetent; however, multiple lesions are usually in the context of immunosuppression, and related to disseminated disease.³⁰ In our case, the patient had a history of trauma, but clinical morphology showed multiple lesions. Combined with coinfection of two opportunistic pathogens, *M. fortuitum* and *T. marneffei*, the patient was considered to have an immunodeficiency disease. We tried to find evidence of immunodeficiency but failed to do so. The young female was HIV-negative, without a history of corticosteroids or immunosuppressive medicine, and no underlying diseases such as structural pulmonary disease, myeloma, autoimmune diseases, hematological malignancies, solid tumors, or diabetes. Her lymphocyte and immunoglobulin levels were also normal. However, with the data provided, we cannot exclude that the patient has an underlying primary immunodeficiency.

There is no specific treatment for *M. fortuitum* infection. It was recently found that rapidly growing mycobacterium harbors mutations in the erythromycin methylase (*erm*) gene, resulting in macrolide resistance.³¹ Macrolides work by binding to the 50S ribosomal subunit and inhibiting peptide synthesis. The *erm* mutant can inhibit binding to ribosomes and reduce the antimicrobial activity of macrolides. Recent guidelines³² recommend treating *M. abscess* pulmonary infection according to the presence or absence of the *erm* mutation. For non-mutant strains, initial treatment should consist of three active drugs including macrolides. For mutant strains, initial treatment should consist of four active drugs including macrolides, which is useful due to its immunomodulatory properties. *M. fortuitum* as a rapidly growing mycobacterium can be treated with the regimen used for *M. abscess*. Recently, an in vitro sensitivity test in Shanghai³³ confirmed that *M. fortuitum* was resistant to macrolides, and the resistance rates to clarithromycin, azithromycin, cefoxitin, and moxifloxacin were 94%, 100%, 88%, and 59%, respectively, while it showed good sensitivity to linezolid and imipenem. In our case, the initial therapy of cefoxitin, moxifloxacin, clarithromycin, and levofloxacin was ineffective. The patient's condition improved after administration of the combination of linezolid, moxifloxacin, clarithromycin and imipenem. However, patients with IFN- γ autoimmune disease may have recurrent infections. Combination with rituximab can reduce the risk of

recurrence. The patient in this study has not experienced disease recurrence to date and is undergoing regular follow-ups.

In summary, *M. fortuitum* is usually considered to have low virulence and causes colonized or transient infection rather than pathopoiesis in the respiratory tract. We report the first case of coinfection with *M. fortuitum* and *T. marneffei* in an HIV-negative patient. This finding serves as a reminder to clinicians that *M. fortuitum* infection may occur in a seemingly healthy patient, and that patients with similar disseminated infections should be evaluated for primary immunodeficiency.

Abbreviations

NTM, non-tuberculous mycobacteriosis; HIV, human immunodeficiency virus; EBUS-TBNA, endobronchial ultrasound-transbronchial lung needle aspiration; qPCR, quantitative polymerase chain reaction; mNGS, metagenomics next-generation sequencing; T-SPOT, T cell spot test; BALF, bronchoalveolar lavage fluid; CT, computed tomography; PAS, periodic acid-Schiff; CFX, cefoxitin; LVFX, levofloxacin; MFX, moxifloxacin; CDZ, cefodizime; CLA, clarithromycin; ETM, etimicin; H, isoniazid; R, rifampicin; Z, pyrazinamide; E, ethambutol; AMPB, amphotericin B liposomes; VRC, voriconazole; LZD, linezolid; *erm*, erythromycin methylase.

Ethics Approval and Informed Consent

Written informed consent to have the case details and any accompanying images published has been provided by the patient. No ethical committee approval was required for this study as the data were analyzed in a retrospective manner.

Acknowledgments

All authors thank the patient and her families for their support.

Author Contributions

All authors made substantial contributions to the conception and design, acquisition of data, or analysis and interpretation of data; participated in drafting the article or revising it substantially, agreed to submit to the current journal, gave final approval of the version to be published; and agreed to take responsibility for all aspects of the work.

Funding

There is no funding to report.

Disclosure

The authors report no conflicts of interest in this work.

References

- Zhuang B, Wu C, Lin G. [Resistance of *Mycobacterium fortuitum* against varied physical factors and its survival in different surroundings]. *Zhonghua Jie He He Hu Xi Za Zhi*. 2001;24(11):679–681. Chinese.
- Okamori S, Asakura T, Nishimura T, et al. Natural history of *Mycobacterium fortuitum* pulmonary infection presenting with migratory infiltrates: a case report with microbiological analysis. *BMC Infect Dis*. 2018;18(1):1. doi:10.1186/s12879-017-2892-9
- Corti M, Soto I, Villafañe F, Esquivel P, Di Lonardo M. [Disseminated infection due to *Mycobacterium fortuitum* in an AIDS patient]. *Medicina (B Aires)*. 1999;59(3):274–276. Spanish.
- To K, Cao R, Yegiazaryan A, Owens J, Venketaraman V. General Overview of Nontuberculous *Mycobacteria* Opportunistic Pathogens: *mycobacterium avium* and *Mycobacterium abscessus*. *J Clin Med*. 2020;9(8):2541. doi:10.3390/jcm9082541
- Shamaei M, Mirsaeidi M. Nontuberculous *Mycobacteria*, Macrophages, and Host Innate Immune Response. *Infect Immun*. 2021;89(8):e0081220. doi:10.1128/IAI.00812-20
- Early J, Fischer K, Bermudez LE. *Mycobacterium avium* uses apoptotic macrophages as tools for spreading. *Microb Pathog*. 2011;50(2):132–139. doi:10.1016/j.micpath.2010.12.004
- Tomioaka H, Tatano Y, Maw WW, Sano C, Kanehiro Y, Shimizu T. Characteristics of suppressor macrophages induced by mycobacterial and protozoal infections in relation to alternatively activated M2 macrophages. *Clin Dev Immunol*. 2012;2012:635451. doi:10.1155/2012/635451
- Thiriot JD, Martinez-Martinez YB, Endsley JJ, Torres AG. Hacking the host: exploitation of macrophage polarization by intracellular bacterial pathogens. *Pathog Dis*. 2020;78(1):ftaa009. doi:10.1093/femspd/ftaa009
- Johansen MD, Kremer L. CFTR Depletion Confers Hypersusceptibility to *Mycobacterium fortuitum* in a Zebrafish Model. *Front Cell Infect Microbiol*. 2020;10:357. doi:10.3389/fcimb.2020.00357
- Lu S, Hu Y, Lu C, Zhang J, Li X, Xi L. Development of in vitro macrophage system to evaluate phagocytosis and intracellular fate of *Penicillium marneffei* conidia. *Mycopathologia*. 2013;176(1–2):11–22. doi:10.1007/s11046-013-9650-3
- Pongpom M, Vanittanakom P, Nimmanee P, Cooper CR Jr, Vanittanakom N. Adaptation to macrophage killing by *Talaromyces marneffei*. *Future Sci OA*. 2017;3(3):FSO215. doi:10.4155/fsoa-2017-0032
- Lu S, Li D, Xi L, Calderone R. Interplay of interferon-gamma and macrophage polarization during *Talaromyces marneffei* infection. *Microb Pathog*. 2019;134:103594. doi:10.1016/j.micpath.2019.103594
- Duan H, Han X, Wang Q, et al. Clinical Significance of Nontuberculous *Mycobacteria* Isolated From Respiratory Specimens in a Chinese Tuberculosis Tertiary Care Center. *Sci Rep*. 2016;6(1):36299. doi:10.1038/srep36299
- Park S, Suh GY, Chung MP, et al. Clinical significance of *Mycobacterium fortuitum* isolated from respiratory specimens. *Respir Med*. 2008;102(3):437–442. doi:10.1016/j.rmed.2007.10.005
- Hirabayashi R, Nakagawa A, Takegawa H, Tomii K. A case of pleural effusion caused by *Mycobacterium fortuitum* and *Mycobacterium mageritense* coinfection. *BMC Infect Dis*. 2019;19(1):720. doi:10.1186/s12879-019-4366-8
- Soto-Arquínigo L, García-Pareja M, Gotuzzo-Herencia E, Legua-Leiva P, Sánchez-Herrera M. [Co-infection by *Mycobacterium fortuitum* and *Mycobacterium tuberculosis* in splenic abscesses in a patient with HIV]. *Rev Peru Med Exp Salud Publica*. 2017;34(2):328–331. doi:10.17843/rpmesp.2017.342.2470. Catalan.
- Su -S-S, Zhang S-N, Ye J-R, et al. <p>Disseminated *Talaromyces marneffei* And *Mycobacterium avium* Infection Accompanied Sweet's Syndrome In A Patient With Anti-Interferon-γ Autoantibodies: a Case Report. *Infect Drug Resist*. 2019;12:3189–3195. doi:10.2147/IDR.S218836
- Xu H, Liu D, He X, Zheng D, Deng Y. Sweet's Syndrome Associated with *Talaromyces marneffei* and *Mycobacterium abscessus* Infection Due to Anti-interferon-gamma Autoantibodies. *Indian J Dermatol*. 2018;63(5):428–430. doi:10.4103/ijd.IJD_362_17
- Pruetpongpan N, Khawcharoenporn T, Damronglerd P, et al. Disseminated *Talaromyces marneffei* and *Mycobacterium abscessus* in a Patient With Anti-Interferon-γ Autoantibodies. *Open Forum Infect Dis*. 2016;3(2):ofw093. doi:10.1093/ofid/ofw093
- Seok H, Ko JH, Shin I, et al. Disseminated *Talaromyces marneffei* and *Mycobacterium intracellulare* coinfection in an HIV-infected patient. *Int J Infect Dis*. 2015;38:86–88. doi:10.1016/j.ijid.2015.07.020
- Zhang J, Huang X, Zhang X, et al. Coinfection of disseminated *Talaromyces marneffei* and *Mycobacteria kansasii* in a patient with papillary thyroid cancer: a case report. *Medicine (Baltimore)*. 2017;96(52):e9072. doi:10.1097/MD.0000000000009072
- Ding X, Huang H, Zhong L, et al. Disseminated *Talaromyces marneffei* Infection in a Non-HIV Infant With a Homozygous Private Variant of RELB. *Front Cell Infect Microbiol*. 2021;11:605589. doi:10.3389/fcimb.2021.605589
- Chetchotisakd P, Kiertiburanakul S, Mootsikapun P, Assanasen S, Chaiwarith R, Anunnatsiri S. Disseminated nontuberculous mycobacterial infection in patients who are not infected with HIV in Thailand. *Clin Infect Dis*. 2007;45(4):421–427. doi:10.1086/520030
- Santos PE, Piontelli E, Shea YR, et al. *Penicillium piceum* infection: diagnosis and successful treatment in chronic granulomatous disease. *Med Mycol*. 2006;44(8):749–753. doi:10.1080/13693780600967089
- Davidson PT. The other mycobacteria. *Chest*. 1979;75(2):110–111. doi:10.1378/chest.75.2.110
- Hien H, Thanh TT, Thu N, et al. Development and evaluation of a real-time polymerase chain reaction assay for the rapid detection of *Talaromyces marneffei* MP1 gene in human plasma. *Mycoses*. 2016;59(12):773–780. doi:10.1111/myc.12530
- Chirasuthat P, Triyangkulsri K, Rutnin S, Chanprapaph K, Vachiramon V. Cutaneous nontuberculous mycobacterial infection in Thailand: a 7-year retrospective review. *Medicine (Baltimore)*. 2020;99(10):e19355. doi:10.1097/MD.00000000000019355
- Ungpakorn R. Cutaneous manifestations of *Penicillium marneffei* infection. *Curr Opin Infect Dis*. 2000;13(2):129–134. doi:10.1097/00001432-200004000-00006
- Lee WJ, Kang SM, Sung H, et al. Non-tuberculous mycobacterial infections of the skin: a retrospective study of 29 cases. *J Dermatol*. 2010;37(11):965–972. doi:10.1111/j.1346-8138.2010.00960.x
- Kothavade RJ, Dhurat RS, Mishra SN, Kothavade UR. Clinical and laboratory aspects of the diagnosis and management of cutaneous and subcutaneous infections caused by rapidly growing mycobacteria. *Eur J Clin Microbiol Infect Dis*. 2013;32(2):161–188. doi:10.1007/s10096-012-1766-8
- Nash KA, Zhang Y, Brown-Elliott BA, Wallace RJ Jr. Molecular basis of intrinsic macrolide resistance in clinical isolates of *Mycobacterium fortuitum*. *J Antimicrob Chemother*. 2005;55(2):170–177. doi:10.1093/jac/dkh523

32. Daley CL, Iaccarino JM, Lange C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: an Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline: executive Summary. *Clin Infect Dis*. 2020;71(4):e1–e36. doi:10.1093/cid/ciaa241
33. Shen Y, Wang X, Jin J, et al. In Vitro Susceptibility of Mycobacterium abscessus and Mycobacterium fortuitum Isolates to 30 Antibiotics. *Biomed Res Int*. 2018;2018:4902941. doi:10.1155/2018/4902941

Infection and Drug Resistance

Dovepress

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of

antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>